<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Abeyasinghe PM</submitter><funding>Medical Research Council</funding><funding>NINDS NIH HHS</funding><funding>National Health and Medical Research Council</funding><funding>Wellcome Trust</funding><pagination>2282-2292</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8590922</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>36(10)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Potential therapeutic targets and clinical trials for Huntington's disease have grown immensely in the last decade. However, to improve clinical trial outcomes, there is a need to better characterize profiles of signs and symptoms across different epochs of the disease to improve selection of participants.&lt;h4>Objective&lt;/h4>The objective of the present study was to best distinguish longitudinal trajectories across different Huntington's disease progression groups.&lt;h4>Methods&lt;/h4>Clinical and morphometric imaging data from 1082 participants across IMAGE-HD, TRACK-HD, and PREDICT-HD studies were combined, with longitudinal times ranging between 1 and 10 years. Participants were classified into 4 groups using CAG and age product. Using multivariate linear mixed modeling, 63 </pubmed_abstract><journal>Movement disorders : official journal of the Movement Disorder Society</journal><pubmed_title>Tracking Huntington's Disease Progression Using Motor, Functional, Cognitive, and Imaging Markers.</pubmed_title><pmcid>PMC8590922</pmcid><funding_grant_id>U01 NS105509</funding_grant_id><funding_grant_id>UKDRI-1008/2</funding_grant_id><funding_grant_id>200181/Z/15/Z</funding_grant_id><funding_grant_id>606650</funding_grant_id><funding_grant_id>U01 NS103475</funding_grant_id><funding_grant_id>R01 NS040068</funding_grant_id><pubmed_authors>Razi A</pubmed_authors><pubmed_authors>Poudel GR</pubmed_authors><pubmed_authors>Abeyasinghe PM</pubmed_authors><pubmed_authors>Tabrizi SJ</pubmed_authors><pubmed_authors>Pustina D</pubmed_authors><pubmed_authors>Georgiou-Karistianis N</pubmed_authors><pubmed_authors>Long JD</pubmed_authors><pubmed_authors>Paulsen JS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Tracking Huntington's Disease Progression Using Motor, Functional, Cognitive, and Imaging Markers.</name><description>&lt;h4>Background&lt;/h4>Potential therapeutic targets and clinical trials for Huntington's disease have grown immensely in the last decade. However, to improve clinical trial outcomes, there is a need to better characterize profiles of signs and symptoms across different epochs of the disease to improve selection of participants.&lt;h4>Objective&lt;/h4>The objective of the present study was to best distinguish longitudinal trajectories across different Huntington's disease progression groups.&lt;h4>Methods&lt;/h4>Clinical and morphometric imaging data from 1082 participants across IMAGE-HD, TRACK-HD, and PREDICT-HD studies were combined, with longitudinal times ranging between 1 and 10 years. Participants were classified into 4 groups using CAG and age product. Using multivariate linear mixed modeling, 63 </description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Oct</publication><modification>2025-04-04T19:52:44.458Z</modification><creation>2025-02-19T02:24:11.026Z</creation></dates><accession>S-EPMC8590922</accession><cross_references><pubmed>34014005</pubmed><doi>10.1002/mds.28650</doi></cross_references></HashMap>